This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Liraglutide
From Proteopedia
(Difference between revisions)
| Line 2: | Line 2: | ||
Liraglutide, sold under the brand name Victoza among others, is an anti-diabetic medication used to treat type 2 diabetes, and chronic obesity. See also [https://en.wikipedia.org/wiki/Liraglutide]. | Liraglutide, sold under the brand name Victoza among others, is an anti-diabetic medication used to treat type 2 diabetes, and chronic obesity. See also [https://en.wikipedia.org/wiki/Liraglutide]. | ||
| - | Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) agonist, derived from human GLP-1-(7-37), a less common form of endogenous GLP-1. See [[Glucagon-like peptide 1 receptor|Glucagon-like peptide-1 and its receptor]]. | + | Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) agonist, derived from human GLP-1-(7-37), a less common form of endogenous GLP-1. See [[Glucagon-like peptide 1 receptor|Glucagon-like peptide-1 and its receptor]] and [[Glucagon]]. |
It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. | It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. | ||
Current revision
| |||||||||||
